2025 年指导
葛兰素史克提供了固定汇率 (CER) 下的全年指导。

• 预计营业额增长3％至5％
• 预计核心营业利润增长6％至8％
• 预计核心每股收益增长6％至8％

此指导的支持来自以下2025年全年固定汇率 (CER) 下的营业额预期：

• 专业药品：预计营业额将低双位数百分比增长
• 疫苗：预计营业额将低单位数百分比下降
• 普通药品：预计营业额基本保持稳定

以上内容来自Benzinga Earnings专栏，原文如下：

2025 Guidance 

GSK provides its full-year guidance at constant exchange rates (CER). 

• Turnover is expected to increase between 3 to 5 per cent 
• Core operating profit is expected to increase between 6 to 8 per cent 
• Core earnings per share is expected to increase between 6 to 8 per cent 

This guidance is supported by the following turnover expectations for full-year 2025 at CER 

• Specialty Medicines – expected increase of a low double-digit per cent in turnover 
• Vaccines – expected decrease of a low single-digit per cent in turnover 
• General Medicines – expected to be broadly stable for turnover